Qiaolin Deng

USPTO Granted Patents = 19 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 11.7

ph-index = 3

Forward Citations = 60(Granted Patents)

Location History:

Princeton, NJ (US) (2021 - 2022)
Edison, NJ (US) (2010 - 2024)

Company Filing History:

18 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 10

Msd R&d (china) Co., Ltd.

where one patent can have more than one assignee

Years Active: 2010-2025

where 'Filed Patents' based on already Granted Patents

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

2. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

3. 12263171 - 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2025-04-01),

4. 12060357 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2024-08-13),

5. 11566057 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2023-01-31),

6. 11492385 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2022-11-08),

7. 11339156 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2022-05-24),

8. 11312719 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2022-04-26),

9. 11149036 - 3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor (2021-10-19),

10. 10793615 - Long-acting co-agonists of the glucagon and GLP-1 receptors (2020-10-06),

11. 10472347 - Aminopyrazine compounds with A2A antagonist properties (2019-11-12),

12. 10413593 - Co-agonists of the glucagon and GLP-1 receptors (2019-09-17),

13. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),

14. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

15. 9676780 - [object Object] (2017-06-13),

Certainly! Here is the article about inventor Qiaolin Deng:

Title: Celebrating the Innovative Mind of Qiaolin Deng

Introduction:

Inventor Qiaolin Deng, a resident of Edison, NJ (US), is a prolific inventor known for his remarkable contributions to the field of medical research and pharmacology. With an impressive portfolio of 15 patents to his name, Deng's inventive spirit shines through in his latest groundbreaking work on long-acting co-agonists of the glucagon and GLP-1 receptors.

Latest Patents:

Deng's recent patents include the development of long-acting co-agonists of the glucagon and GLP-1 receptors, revolutionizing the treatment options for metabolic disorders. This innovative approach showcases Deng's commitment to pushing the boundaries of medical science and improving the lives of patients globally.

Career Highlights:

Throughout his career, Qiaolin Deng has made significant contributions to the pharmaceutical industry, having worked with esteemed companies such as Merck Sharp & Dohme Corporation and MSD R&D (China) Co., Ltd. His dedication to innovation and excellence has been instrumental in driving forward advancements in the field of biopharmaceuticals.

Collaborations:

Deng's collaborative efforts with industry peers like Amjad Ali and Zhijian Lu have led to the development of cutting-edge solutions that address unmet medical needs. By fostering a culture of teamwork and knowledge sharing, Deng has been able to leverage diverse perspectives to fuel his inventive endeavors.

Conclusion:

In conclusion, Qiaolin Deng's inventive brilliance and unwavering commitment to innovation have solidified his position as a pioneer in the field of medical research. His impressive track record of patents, coupled with his collaborative spirit, exemplifies the transformative power of ingenuity in shaping the future of healthcare. Qiaolin Deng's contributions continue to inspire and pave the way for new possibilities in the realm of biopharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.